BioNexus Gene Lab Corp. (BGLC)
NASDAQ: BGLC · Real-Time Price · USD
2.180
+0.010 (0.46%)
At close: Apr 15, 2026, 4:00 PM EDT
2.250
+0.070 (3.21%)
After-hours: Apr 15, 2026, 6:45 PM EDT
BioNexus Gene Lab Revenue
In the year 2025, BioNexus Gene Lab had annual revenue of $7.42M, down -21.93%. BioNexus Gene Lab had revenue of $483.76K in the quarter ending December 31, 2025, a decrease of -80.83%.
Revenue (ttm)
$7.42M
Revenue Growth
-21.93%
P/S Ratio
0.69
Revenue / Employee
$247,497
Employees
30
Market Cap
5.15M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.42M | -2.09M | -21.93% |
| Dec 31, 2024 | 9.51M | -260.16K | -2.66% |
| Dec 31, 2023 | 9.77M | -1.16M | -10.60% |
| Dec 31, 2022 | 10.93M | -2.43M | -18.21% |
| Dec 31, 2021 | 13.36M | 1.97M | 17.31% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Aemetis | 207.98M |
| Montauk Renewables | 176.38M |
| FutureFuel | 95.74M |
| Northern Technologies International | 89.13M |
| Flexible Solutions International | 38.56M |
| CN Energy Group. | 35.57M |
| J-Star Holding | 20.05M |
| Bon Natural Life | 18.67M |
BGLC News
- 5 weeks ago - BioNexus Gene Lab Corp. Announces Appointment of Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics to Lead Global Commercialization of the VitaGuard™ MRD Platform - GlobeNewsWire
- 7 weeks ago - BioNexus Gene Lab Corp. Completes Chemrex Governance Restructuring; Appoints Matthew Barsing as Chairman - GlobeNewsWire
- 2 months ago - BioNexus Launches Regional Deployment of VitaGuard™ MRD Infrastructure; Positioned to Challenge Legacy Oncology Platforms Across ASEAN's Multi-Billion Dollar Market - GlobeNewsWire
- 4 months ago - BioNexus Gene Lab Corp. Completes Strategic Investment in Fidelion Diagnostics; Secures 15% Equity Stake in Global AI-Oncology Platform and Exclusive Southeast Asian Rights for VitaGuard™ - GlobeNewsWire
- 4 months ago - BioNexus Gene Lab Corp. (Nasdaq: BGLC) Secures $500 Million Equity Facility From ARC Group International to Support Expansion of Precision Diagnostics, CDMO Operations, and Therapeutic Commercialization - GlobeNewsWire
- 4 months ago - BioNexus Gene Lab Corp. (Nasdaq: BGLC) and Fidelion Diagnostics Execute Exclusive Southeast Asia License for VitaGuard™ MRD Platform as Part of Strategic Alliance with Tongshu Gene - GlobeNewsWire
- 5 months ago - BioNexus Gene Lab Corp. (Nasdaq: BGLC) Announces Strategic Agreements with Fidelion Diagnostics for Southeast Asia MRD Commercialization - GlobeNewsWire
- 5 months ago - BioNexus Gene Lab Corp. Files $100 Million Shelf Registration and Establishes $20 Million At-the-Market Program to Advance Strategic Growth Opportunities - GlobeNewsWire